Community

Advertising Opportunities

 Biotechnology Europe Programs

 Resources

Biotechnology Europe Community

Feedback

Contact

Biotechnology Europe Advantages

Advertising Opportunities on Biotechnology Europe

Sponsorship Opportunities on Biotechnology Europe

 

Post a Job on Biotechnology Europe

Post a Company Profile on Biotechnology Europe

Post a News on Biotechnology Europe

Post an Event on Biotechnology Europe

Post a Product on Biotechnology Europe

Post a Publication on Biotechnology Europe

Post a Technology on Biotechnology Europe

Post a Resume on Biotechnology Europe

Terms of Business

Imprint

Privacy Policy

FAQ

Subscribe Newsletter

 

Axis-Shield News

   

 

 

   
     

   
 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   

post your news I subscribe newsletter I contact us

 
 
   

 

Axis-Shield Acknowledges World Diabetes Day and Provides an Update on its Growing Diabetes Franchise in Emerging Markets

15th November 2010 Dundee, Scotland

 

Axis-Shield (LSE:ASD, OSE:ASD), (“Axis-Shield” or “the Company”), the international and innovative in vitro diagnostics company, today announces its participation in World Diabetes Day, a global campaign led by the International Diabetes Foundation to engage people in diabetes advocacy and awareness. Diabetes Education and Prevention is the World Diabetes Day theme for the period 2009-2013 and the campaign slogan for 2010 is 'Let's take control of diabetes Now.' The Axis-Shield Point-of-Care (“PoC”) offices in Oslo and Dundee will mark the day with a number of initiatives across its global sites and has encouraged all Axis-Shield subsidiaries and distributors to do the same. Axis-Shield is present in 80 countries around the world and continues to broaden its global presence through the growth of its important diabetes testing franchise.
 

Diabetes presents a growing burden on the world’s economy and will shift the drive to PoC testing in emerging markets, regions where Axis-Shield is well positioned to be part of this change with its highly innovative Afinion™ and NycoCard® PoC diagnostic HbA1c tests for diabetes. HbA1c is clinically recognised as the key marker for diabetes management1, reflecting how well the patient hasmanaged blood glucose levels over the preceding three months and is the fastest growing segment of the global PoC test market.

 

A key driver of growth for Axis-Shield is its presence in emerging markets where the Company’s highquality and established NycoCard® test platform for HbA1c is extremely well suited to diabetes management, offering simple, accurate and fast testing at the PoC. Axis-Shield is investing in developing its brand in emerging markets and regularly hosts educational workshops, seminars and other marketing activities with its distribution partners and via collaborations with pharmaceutical companies in certain regions to increase awareness of the need for regular testing and management of diabetes.
 

At present, Axis-Shield’s emerging market strategy is focused on the establishment and growth of PoC for diabetes in the top five emerging markets; China, India, Indonesia, Mexico and Brazil. India has the highest population of people affected by diabetes globally2 and a recent study published in the New England Journal of Medicine has demonstrated that diabetes has reached epidemic proportions in China3.
 

Axis-Shield is also replicating this strategy in other areas in which diabetes prevalence is increasing quickly, notably Argentina, Brazil, Nigeria, Russia and the Middle East.
 

Axis-Shield has strengthened its sales team during 2010 to include a locally-based Area Manager in Latin America with responsibility for broadening the Company’s presence and establishing PoC testing regimes in nascent territories. In addition, Axis-Shield has also recruited an Area Manager with an appreciation of the relevant cultures to spearhead growth in Africa and the Middle East.
 

China

Axis-Shield opened a representative office in China in 2009 and is committed to the growth of its regional franchise through the addition of up to 18 regional dealers in 2011 to utilize NycoCard® and Afinion™ PoC testing potential. China’s population is expected to reach 1.4bn by the end of 2010 but it only currently accounts for 4% of the global in vitro diagnostics (“IVD”) market. The PoC testing market is growing rapidly, driven by the Chinese Government’s decision to provide acceptable healthcare to people living in small cities and rural areas. The adoption of HbA1c usage in the diagnosis of diabetes will also push the development of the HbA1c testing
 

India

The Indian Government is focused on improving healthcare, highlighted by its launch in 2005 of the national Rural Health Mission. Both Axis-Shield’s Afinion™ and NycoCard® systems are positioned to aid physicians in addressing growing diabetes issues. NycoCard® is already a market leader in PoC diagnostic testing in India and with increasing demand for better and effective healthcare particular in the cities, Afinion™ will be a driver in the HbA1c PoC testing.
 

Latin America

The prevalence of diabetes in Latin America is increasing and there is a rapidly growing need for immediate HbA1c results, improved patient care and healthcare savings due to the impact of realising cost efficiencies and the awareness of long-term diabetes complications. Axis-Shield will launch Afinion™ in Mexico in late 2010 and Brazil will follow in 2011 as part of its strategy to strengthen the current PoC markets which are in their infancy. NycoCard® already has a strong market position in Mexico and established successful partnerships with pharmaceutical companies and healthcare providers through our local partner. This has focused on addressing the need to offer innovative access to PoC testing and the Company has had particular success in the workplace, through the use of mobile testing sites. Axis-Shield and its partners will continue the roll-out of this strategy throughout Latin America.
 

Africa

Africa offers a vast potential market for Axis-Shield as it seeks to broaden its presence beyond the Northern region into West Africa. The political and economic climate is improving in these regions and there is a growing awareness of the need to offer greatly improved healthcare solutions.
 

Middle East

The Middle Eastern healthcare market is showing encouraging regional signs of improvement and the NycoCard® market is already growing with significant room for growth in this high value market remaining apparent. Axis-Shield’s strategy to market NycoCard® in the Gulf countries is already delivering promising results. The Company also sees significant market potential for Afinion™.
 

Other emerging markets

Axis-Shield has demonstrated recent sales penetration and the potential for growth in Bangladesh, Vietnam and Malaysia where there is a high incidence of diabetes and currently a centralized testing strategy with demand for PoC testing via NycoCard® increasing.
 

Commenting on today’s announcement, Ian Gilham, Chief Executive Officer of Axis-Shield, said:

“Axis-Shield is pleased to be a provider of diabetes Point of Care testing in emerging markets where there is a huge unmet medical need to deliver patient care of the highest quality. Our established infrastructure and broad product offering via Afinion™ and NycoCard® positions us as a pioneer of HbA1c testing solutions globally and we remain focused on raising awareness of the need for accurate testing and management.
 

“Whilst the concept of HbA1c Point of Care testing is still in its infancy in Latin America, Asia, Africa and the Middle East, we are committed to investing in emerging markets and are focused on growth in these important markets and disease area.”

 

Axis-Shield plc

Tel: +44 (0) 20 3178 7849

Ian Gilham, Chief Executive Officer Ronny Hermansen, Finance Director

 

 

Tel: +44 (0) 20 7920 2330

M:Communications Mary-Jane Elliott / Emma Thompson / Amber BieleckaAxisshield@mcomgroup.com

 

 

About Axis-Shield

Axis-Shield is an international in vitro diagnostics company, headquartered in Dundee with R&D and manufacturing bases in Dundee and Oslo. The Group specialises in the supply of instruments and tests for the rapidly growing physician’s office testing market and the development, manufacture and marketing of innovative proprietary diagnostics kits in areas of clinical need, including cardiovascular and neurological diseases, rheumatoid arthritis, sepsis and diabetes.

 

For more information on Axis-Shield, please refer to www.axis-shield.com.

 

About Afinion™

Afinion™ is a new concept in Point of Care – a multiparameter rapid analyser system with minimal user input and sample handling. Afinion™ is designed to enable on-the-spot testing, using whole blood, plasma or urine samples, and to deliver accurate results during patient consultation for improved patient management. The analyser and test cartridges have been precision engineered by external organisations according to Axis-Shield designs and specifications, with each test cartridge containing an integrated sample collection device and all necessary reagents for one single analysis.
 

By the end of 2010 the Company expects to have placed 10,000 systems globally.
 

About NycoCard®

The NycoCard® System is Axis-Shield’s most widely distributed product range particularly suited to countries with developing healthcare systems. It represents a versatile, low-cost package designed to deliver reliable testing for certain key markers, in the presence of the patient. The system offers four selected PoC tests: CRP, HbA1c, D-Dimer and U-Albumin. They can all be analysed on the same instrument – the NycoCard Reader II. The Reader is a small portable battery-powered instrument designed for rapid and reliable measurement using NycoCard® tests. It consists of two units: the instrument box, which is the operational and calculating unit, and the Reader pen, which detects the signal. Globally there are a large number of installed systems and Axis-Shield estimates over 40,000 units are currently in operation.

 

1 The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–86.

2 International Diabetes Federation. Diabetes Atlas, 4th edition. www.eatlas.idf.org

3 New England Journal of Medicine, Prevalence of Diabetes among Men and Women in China. 362; 12, March 25, 2010

 

 

 


 
 
   
28.10.2010 Axis-Shield Plc Interim Management Statement  
Axis-Shield (LSE:ASD, OSE:ASD), (“Axis-Shield” or “the Company”), the innovative international in vitro diagnostics company, today issues an Interim Management Statement for the 17 week period ending 27 October 2010.
 
   
27.10.2010 Axis-Shield Named “Vendor of the Year” Award for Afinion by PSS in the USA for the Second Consecutive Year  
Axis-Shield (LSE:ASD, OSE:ASD), (“Axis-Shield” or “the Company”), the innovative international in-vitro diagnostics (IVD) company, today announces that it has been named “Vendor of the Year” for Afinion™ by Physician Sales & Service, Inc. (PSS), the largest distributor of medical supplies and services to office-based physicians in the United States, for an unprecedented second consecutive year.    
 
   
13.10.2010 Bio-Rad and Axis-Shield Announce FDA Clearance and U.S. launch of an Anti-CCP Test for Rheumatoid Arthritis for Bio-Rad’s BioPlex® 2200 System  
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a multinational manufacturer and distributor of life science research and clinical diagnostics products, and Axis-Shield (LSE:ASD, OSE:ASD), an international and innovative in-vitro diagnostics company, today announced the U.S. Food and Drug Administration (FDA) clearance and U.S. launch of Bio-Rad’s BioPlex® 2200 Anti-CCP test for the early detection of rheumatoid arthritis. The assay, which runs on Bio-Rad's BioPlex® 2200 system, measures anti-CCP (anti-cyclic citrullinated peptide antibodies), a novel marker that has been shown to have superior specificity in the diagnosis of rheumatoid arthritis. The BioPlex® 2200 Anti-CCP assay is based on Axis-Shield’s proprietary anti-CCP technology and was launched in territories outside the U.S. earlier in 2010.
 
   
23.06.2010 Axis-Shield Announces Launch of New Anti-CCP Test for Rheumatoid Arthritis on the Zenit RA Analyser  
Axis-Shield (LSE:ASD, OSE:ASD),  the international in-vitro diagnostics (IVD) company, today announces the launch of an automated anti-CCP test for the early detection of rheumatoid arthritis on the new Zenit RA analyser system. The assay is based on Axis-Shield’s proprietary technology and measures antibodies against cyclic citrullinated peptides (anti-CCP), a novel marker that has been shown to have superior specificity in the diagnosis of rheumatoid arthritis. The assay and system are being launched by Technogenetics of Italy (part of the Bouty Healthcare Group), through an exclusive European distribution agreement with Menarini, and will be available for sale outside the USA.
 
   
16.03.2010 Board Changes  
Axis-Shield (LSE:ASD, OSE:ASD), the international in vitro diagnostics (IVD) company, today announces the appointment of Dr John Brown PhD MBA FRSE as Chairman designate. Dr Brown will succeed Nigel Keen, who will step down as Chairman and retire from the Board at the conclusion of the Company’s Annual General Meeting on 13 May, 2010. His appointment follows an internal process led by Staffan Ek, an Independent Non-Executive Director of Axis-Shield, which culminated in the Board’s unanimous resolution to appoint Dr Brown as the new Chairman.
 
   
   

 
 
 
Custom Search
 
 I back I top I  

 

 

                                                                

office@biotechnology-europe.com I website@biotechnology-europe.com I service@biotechnology-europe.com

 


 

Advertising Opportunities on Biotechnology Europe

Sponsorship Opportunities on Biotechnology Europe

About Biotechnology Europe

Post a Job on Biotechnology Europe

Post a Company Profile on Biotechnology Europe

Post a News on Biotechnology Europe

Post an Event on Biotechnology Europe

Post a Product on Biotechnology Europe

Post a Publication on Biotechnology Europe

Post a Technology on Biotechnology Europe

Post a Resume on Biotechnology Europe


 

Biotechnology Europe Your Partner in Bioscience and Business

  Central Internet Platform and Service Company For The Life Sciences in Europe

Imprint I Site map I Privacy Policy I Contact us I About us I Copyright BIOTECHNOLOGY WORLD  All rights reserved

 

                                                                 

office@biotechnology-europe.com I website@biotechnology-europe.com I service@biotechnology-europe.com

 


 

Advertising Opportunities on Biotechnology Europe

Sponsorship Opportunities on Biotechnology Europe

About Biotechnology Europe

Post a Job on Biotechnology Europe

Post a Company Profile on Biotechnology Europe

Post a News on Biotechnology Europe

Post an Event on Biotechnology Europe

Post a Product on Biotechnology Europe

Post a Publication on Biotechnology Europe

Post a Technology on Biotechnology Europe

Post a Resume on Biotechnology Europe


 

Biotechnology Europe Your Partner in Bioscience and Business

  Central Internet Platform and Service Company For The Life Sciences in Europe

Imprint I Site map I Privacy Policy I Contact us I About us I Copyright BIOTECHNOLOGY WORLD  All rights reserved

 

                    

office@biotechnology-europe.com I website@biotechnology-europe.com I service@biotechnology-europe.com

 


 

Advertising Opportunities on Biotechnology Europe

Sponsorship Opportunities on Biotechnology Europe

About Biotechnology Europe

Post a Job on Biotechnology Europe

Post a Company Profile on Biotechnology Europe

Post a News on Biotechnology Europe

Post an Event on Biotechnology Europe

Post a Product on Biotechnology Europe

Post a Publication on Biotechnology Europe

Post a Technology on Biotechnology Europe

Post a Resume on Biotechnology Europe


 

Biotechnology Europe Your Partner in Bioscience and Business

  Central Internet Platform and Service Company For The Life Sciences in Europe

Imprint I Site map I Privacy Policy I Contact us I About us I Copyright BIOTECHNOLOGY WORLD  All rights reserved

 

               

                    

office@biotechnology-europe.com I website@biotechnology-europe.com I service@biotechnology-europe.com

 


 

Advertising Opportunities on Biotechnology Europe

Sponsorship Opportunities on Biotechnology Europe

About Biotechnology Europe

Post a Job on Biotechnology Europe

Post a Company Profile on Biotechnology Europe

Post a News on Biotechnology Europe

Post an Event on Biotechnology Europe

Post a Product on Biotechnology Europe

Post a Publication on Biotechnology Europe

Post a Technology on Biotechnology Europe

Post a Resume on Biotechnology Europe


 

Biotechnology Europe Your Partner in Bioscience and Business

  Central Internet Platform and Service Company For The Life Sciences in Europe

Imprint I Site map I Privacy Policy I Contact us I About us I Copyright BIOTECHNOLOGY WORLD  All rights reserved

 

               

                    

office@biotechnology-europe.com I website@biotechnology-europe.com I service@biotechnology-europe.com

 


 

Advertising Opportunities on Biotechnology Europe

Sponsorship Opportunities on Biotechnology Europe

About Biotechnology Europe

Post a Job on Biotechnology Europe

Post a Company Profile on Biotechnology Europe

Post a News on Biotechnology Europe

Post an Event on Biotechnology Europe

Post a Product on Biotechnology Europe

Post a Publication on Biotechnology Europe

Post a Technology on Biotechnology Europe

Post a Resume on Biotechnology Europe


 

Biotechnology Europe Your Partner in Bioscience and Business

  Central Internet Platform and Service Company For The Life Sciences in Europe

Imprint I Site map I Privacy Policy I Contact us I About us I Copyright BIOTECHNOLOGY WORLD  All rights reserved